

Resource Summary Report

Generated by [dkNET](#) on Aug 22, 2026

CalcuSyn

RRID:SCR_020251

Type: Tool

Proper Citation

CalcuSyn (RRID:SCR_020251)

Resource Information

URL: <http://www.biosoft.com/w/calculusyn.htm>

Proper Citation: CalcuSyn (RRID:SCR_020251)

Description: Software tool for drug mixtures study and establishing efficacy. Dose effect analyzer of combined drugs. Able to quantify synergism and inhibition. CalcuSyn Version 2.0 has Undo and Redo tools.

Synonyms: CalcuSyn Version 2.0

Resource Type: data analysis software, data processing software, software application, software resource

Keywords: Biosoft, drug mixtures study, drug efficacy, dose effect, quantify synergism, quantify inhibition

Availability: Restricted

Resource Name: CalcuSyn

Resource ID: SCR_020251

Record Creation Time: 20220129T080349+0000

Record Last Update: 20260821T194146+0000

Ratings and Alerts

No rating or validation information has been found for CalcuSyn.

No alerts have been found for CalcuSyn.

Data and Source Information

Usage and Citation Metrics

We found 68 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Kang M, et al. (2026) Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. *Molecular cancer therapeutics*, 25(5), 814.

Zhuang R, et al. (2026) PDHA1-acetylation signaling suppresses cuproptosis to attenuate anti-androgen effect in prostate cancer. *Cell death & disease*, 17(1).

Çelik B, et al. (2026) Targeting STAT5A via CRISPR/Cas9 restores TKI sensitivity in resistant chronic myeloid leukemia cells. *Medical oncology (Northwood, London, England)*, 43(6).

Akocak S, et al. (2026) Design and Synthesis of 4-Arylazo Pyrazole Carboxamides as Dual AChE/BChE Inhibitors: Kinetic and In Silico Evaluation. *Pharmaceuticals (Basel, Switzerland)*, 19(2).

Zeljкови? V, et al. (2026) Molecular Insights into the Interaction Between Metformin and Caffeine: The Time-Dependent Antagonism and Modulation of p53 Signaling in Cancer Cells. *Molecules (Basel, Switzerland)*, 31(11).

Keser M, et al. (2025) Design, Synthesis, and Molecular Docking of Triazole-Coumarin Hybrids as Potent Breast Cancer Inhibitors Targeting Cell Cycle and Apoptosis. *Chemistry & biodiversity*, 22(12), e01775.

Spender LC, et al. (2025) AKT/mTOR as a targetable hub to overcome multimodal resistance to EGFR inhibitors in oesophageal squamous cell carcinoma. *British journal of cancer*, 133(5), 709.

Massa A, et al. (2025) Doxycycline Restores Gemcitabine Sensitivity in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma. *Cancers*, 17(1).

Anastasio G, et al. (2025) Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors. *iScience*, 28(2), 111842.

Xing HB, et al. (2025) Resveratrol synergizes with cisplatin to suppress osteosarcoma U2-OS cells via up-regulating Cx43 and inducing ROS-dependent apoptosis. *Discover oncology*, 16(1), 2218.

Araújo NM, et al. (2025) The antitumor effect of tlr4 inhibition in head and neck cancer cell lines. *Scientific reports*, 15(1), 31681.

Oh S, et al. (2025) The Synergistic Effect of PARP Inhibitors and Irinotecan in Small Cell Lung Cancer Cells. *Cancer research and treatment*, 57(4), 1040.

Meric-Bernstam F, et al. (2025) Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(3), 573.

Lan YY, et al. (2025) Combination treatment of cordycepin and radiation induces apoptosis accompanied by protective autophagy in TM3 mouse Leydig progenitor cells. *Journal of food and drug analysis*, 33(4), 471.

Melcón-Fernández E, et al. (2024) In Vitro and Ex Vivo Synergistic Effect of Pyrvinium Pamoate Combined with Miltefosine and Paromomycin against Leishmania. *Tropical medicine and infectious disease*, 9(2).

Chen SY, et al. (2024) Advancing Lung Cancer Treatment with Combined c-Met Promoter-Driven Oncolytic Adenovirus and Rapamycin. *Cells*, 13(18).

Bojkova D, et al. (2023) Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform. *iScience*, 26(2), 105944.

Li Y, et al. (2023) Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. *Journal of experimental & clinical cancer research : CR*, 42(1), 6.

Centonze G, et al. (2023) p140Cap modulates the mevalonate pathway decreasing cell migration and enhancing drug sensitivity in breast cancer cells. *Cell death & disease*, 14(12), 849.

Melcon-Fernandez E, et al. (2023) Miltefosine and Nifuratel Combination: A Promising Therapy for the Treatment of Leishmania donovani Visceral Leishmaniasis. *International journal of molecular sciences*, 24(2).